Navigation Links
Skinvisible Patent Granted for Japan
Date:3/11/2009

- - - Patent Protection Expands for Dermatology Products with Invisicare

LAS VEGAS, March 11 /PRNewswire-FirstCall/ -- Skinvisible, Inc. (OTC Bulletin Board: SKVI) (Website: www.skinvisible.com), is pleased to announce that it has been granted a comprehensive patent in Japan for Invisicare, a product-enhancing polymer delivery system for topical dermatology products. The patent protects Invisicare in the areas of 'Topical Composition,' 'Topical Composition Precursor,' and 'Methods for Manufacturing and Using.'

(Logo: http://www.newscom.com/cgi-bin/prnh/20030416/LAW068LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20040503/INVISICARELOGO)

Skinvisible's strong intellectual property protection is often the key catalyst for a company to license products formulated with Invisicare. Skinvisible's patents provide a guaranteed period of market exclusivity to licensees. Along with developing its own formulations, Skinvisible's research and development team works directly with companies offering life cycle management for their products coming off patent. Additionally, Invisicare offers unique attributes to topical products including the ability to hold active ingredients on the skin for extended periods of time and providing a controlled, fast or slow release of the active ingredient.

"Skinvisible continues to invest into patent protection for Invisicare and its unique characteristics," said Mr. Terry Howlett, President and CEO of Skinvisible. "The strength of our patents is paramount in the success of our product licensing strategy as pharmaceutical companies worldwide battle strong competition for their own products coming off patent. Along with a new patent, Invisicare provides an exciting new marketing story for companies to utilize."

In addition to this new patent approval for Japan, Skinvisible holds patent protection in the United States, Australia and India and has numerous US and international product patents pending.

About Invisicare

Invisicare is Skinvisible's patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. It is a combination of hydrophilic and hydrophobic polymers that hold active ingredients on the skin for extended periods of time resisting both wash off and perspiration. Invisicare can control the release of actives, reduce irritation and can eliminate some costly manufacturing processes. It is non-occlusive and allows for normal skin respiration while protecting against environmental irritants. www.invisicare.com

About Skinvisible Pharmaceuticals, Inc.

Skinvisible Pharmaceuticals is a research-and-development company whose primary business objective is to license its proprietary formulations with Invisicare to pharmaceutical and cosmeceutical companies as well as assisting companies in enhancing their existing skin care products. Skinvisible receives a combination of research and development fees, upfront license fees, and ongoing royalties for the life of the Invisicare patent. Skinvisible's value also lies in its ability to continually generate new IP on dermatology and medical products formulated with Invisicare. www.skinvisible.com

Forward-Looking Statements: This press release contains 'forward looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10Q for the quarter ending September 30, 2008).

    Corporate Contact:
    Doreen McMorran, VP Business Development
    Skinvisible Pharmaceuticals, Inc.
    Phone: 702-433-7154
    Email: info@skinvisible.com


'/>"/>
SOURCE Skinvisible, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Skinvisible Signs Dermatology Agreement With RHEI Pharmaceuticals
2. Skinvisible and Cambrex Enter Into Agreement to Develop Acne Products
3. Skinvisible Appoints Dr. Geert Cauwenbergh to Its International Advisory Board
4. Skinvisible Offers 8 Hour Photostablity for Parsol 1789
5. Skinvisible Appoints New Vice President of Business Development & Marketing
6. Skinvisible Signs Licensing Agreement for Two Acne Formulations
7. Skinvisible Appoints New Board Member
8. Skinvisible Announces Licensing Agreement for Adapalene
9. Skinvisible Signs Marketing Agreement for India
10. Skinvisible Appoints Dr. George Korkos to Its Advisory Board
11. Skinvisible to Present at Merriman Curhan Ford & Co.s Investor Summit 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh ... the Peace Agreements being discussed by President Donald Trump and the rest of the ... to speed up peace talks in the continuous battle between Israel and Palestine. The ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... “When the ... Lead Home” is the creation of published author Laura Weigel Douglas, an avid reader ... cat in a house that sometimes feels like Green Hills Adventure Camp. She couldn’t ...
(Date:5/26/2017)... ... May 26, 2017 , ... “Cactus Jack: Against All Odds”: ... many others. “Cactus Jack: Against All Odds” is the creation of published author, ... Hubbard is married to Jack Carlisle’s third child Jane. Walter. Walter and Jane ...
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... Dr. Alan ... surgery in New York City. He is known for his distinguished expertise and ... vascular surgery, Dr. Benvenisty holds sub-specialty training in treating renovascular disease and aortic ...
(Date:5/24/2017)... ... ... Dr. Manju R. Kejriwal, a leading Ohio dentist, is now welcoming new ... Dr. Kejriwal understands the emotional and financial toll traditional orthodontics can take on patients’ ... longer need to feel the esthetic effects of wires and brackets when they can ...
Breaking Medicine News(10 mins):
(Date:5/18/2017)... May 17, 2017  Bayer announced today that the ... be presented at the 53 rd Annual Meeting ... place June 2-6 in Chicago . ... span prostate, colorectal, liver and thyroid cancers, as well ... Phase II CHRONOS-1 trial of copanlisib in patients with ...
(Date:5/15/2017)... 2017 Enterin Inc., a privately-held CNS pharmaceutical company ... compounds to treat Parkinson,s disease (PD), has enrolled the first ... 1/2a randomized, controlled, multicenter study involving patients with PD and ... patients over a 9-to-12-month period. The first stage is open ... PD. Participating sites include Denver , ...
(Date:5/11/2017)...  Thornhill Research Inc. ( Toronto, Ontario, ... USD five-year, firm-fixed-priced, indefinite-quantity/indefinite-delivery contract by the U.S. ... (CCC) ( Ottawa, Ontario, Canada ) ... anesthesia to patients requiring emergency medical procedures in ... Corps have been a longtime partner with Thornhill ...
Breaking Medicine Technology: